The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma
Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks
The Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOCIETY | Published : 2019
Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and require life-long surveillance. Current guidelines recommend periodic whole-body MRI imaging. We assessed the incremental value of 68Ga-DOTA-octreotate (GaTate) positron emission tomography (PET)/CT compared with conventional imaging in such patients. Methods: SDHx mutation carriers who had GaTate PET/CT were retrospectively reviewed. Detection of lesions were compared with MRI or CT on a per-patient and per-lesion basis. Proof of lesions were based on histopathology or clinical/imaging follow-up. Results: Twenty consecutive patients (median age, 46 years; 10 males) w..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council Practitioner Fellowship
M.H. received institutional research and advisory board meeting funding from Endocyte and from Ipsen and Sanofi Genzyme for speaker fees (none directly related to this research) and is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation. R.H. is supported by a National Health and Medical Research Council Practitioner Fellowship (APP1108050). He also declares that he holds share in Telix Pharmaceuticals on behalf of his institution. The remaining authors have nothing to disclose.